Scutellarin Alleviates Bone Marrow Mesenchymal Stromal Cellular Senescence via the Ezh2‐Nrf2 Signalling Axis in Diabetes‐Induced Bone Loss
Cell Proliferation · 2025
DOI: 10.1111/cpr.13790 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cell Proliferation, 2025. Verfasst von Tiantian Wang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Institute of Neurology and Disease, West China Hospital of Sichuan University, Chengdu, China. Hauptthemen laut MEDLINE: Cellular Senescence, Enhancer of Zeste Homolog 2 Protein, NF-E2-Related Factor 2, Apigenin. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key Research and Development Program of China, the PostDoctor Research Project, West China Hospital, Sichuan University, Joint Funds of the National Natural Science Foundation of China.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Currently, there is no specific treatment for diabetes‐induced osteoporosis (DOP). Our study identified diabetes‐induced cellular senescence, marked by elevated activity of senescence‐associated β‐galactosidase. Targeting senescent cells holds promise for osteoporosis treatment. We demonstrated that scutellarin (SCU) effectively mitigated bone loss in DOP mice, and co‐treatment with SCU significantly reduced diabetes‐induced senescence in LepR+MSCs. Furthermore, our research highlighted the role of Nrf2 in SCU's anti‐senescence effects on bone. The deletion of Nrf2 impaired SCU's ability to alleviate DOP. Mechanistically, SCU enhances Ezh2 expression and increases H3K27me3 activity at the Keap1 promoter region, leading to Keap1 repression and enhanced Nrf2‐ARE signalling. Additionally, SCU notably inhibited cellular senescence and diabetes‐related osteoporosis, these effects were significantly reduced in Ezh2 LepRcre conditional knockout models. These findings suggest that the Ezh2‐Nrf2 signalling axis is crucial for mediating SCU's beneficial effects in this context. Overall, our discoveries provide insights into the mechanisms underlying DOP and propose a potential preventive strategy for this condition.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Institute of Neurology and Disease, West China Hospital of Sichuan University, Chengdu, China.
- Institute of Brain Science and Brain-Inspired Technology of West China Hospital, Sichuan University, Chengdu, China.
- Department of Neurology, Chengdu Shangjin Nanfu Hospital, Chengdu, China.
- Animal Laboratory Center, West China Hospital, Sichuan University, Chengdu, China.
- Department of Orthopedics, The First Affiliated Hospital of Chengdu Medical College, Chengdu, China.
ORCID-Profile: Tiantian Wang
Förderung
- National Key Research and Development Program of China
- the PostDoctor Research Project, West China Hospital, Sichuan University
- Joint Funds of the National Natural Science Foundation of China
- National Natural Science Foundation of China
- Sichuan Science and Technology Program
Zitieren
APA
Wang, T., Chen, J., Qu, B., Zhou, D., & Hong, Z. (2025). Scutellarin Alleviates Bone Marrow Mesenchymal Stromal Cellular Senescence via the Ezh2‐Nrf2 Signalling Axis in Diabetes‐Induced Bone Loss. Cell Proliferation. https://doi.org/10.1111/cpr.13790
Vancouver
Wang T, Chen J, Qu B, Zhou D, Hong Z. Scutellarin Alleviates Bone Marrow Mesenchymal Stromal Cellular Senescence via the Ezh2‐Nrf2 Signalling Axis in Diabetes‐Induced Bone Loss. Cell Proliferation. 2025. doi:10.1111/cpr.13790
BibTeX
@article{Wang2025,
author = {Wang, Tiantian and Chen, Jiehao and Qu, Bo and Zhou, Dong and Hong, Zhen},
title = {Scutellarin Alleviates Bone Marrow Mesenchymal Stromal Cellular Senescence via the Ezh2‐Nrf2 Signalling Axis in Diabetes‐Induced Bone Loss},
journal = {Cell Proliferation},
year = {2025},
doi = {10.1111/cpr.13790}
}
EUVIMED